Ryvu Therapeutics and BioNTech Enter Strategic Agreement for Cancer Immunotherapy Clinical Trials in Poland

Ryvu Therapeutics, a clinical-stage drug discovery and development company, has entered a strategic agreement with BioNTech to support clinical trials for investigational cancer immunotherapies in Poland. The agreement aims to accelerate site activation and patient enrollment for multiple of BioNTech's priority oncology clinical programs in Poland. Ryvu will leverage its clinical network to streamline access to BioNTech's investigational immunotherapies for Polish patients.

Key Takeaways:

Ryvu Therapeutics will support BioNTech in accelerating site activation and patient enrollment for multiple priority oncology clinical programs in Poland.
The agreement aims to streamline access to BioNTech's investigational immunotherapies for Polish patients, with clinical programs spanning multiple solid tumor types, including lung, breast, and colorectal cancers.
Ryvu will leverage its operational excellence, expertise in oncology clinical operations, and existing trial site network to support BioNTech's clinical trials in Poland.
The agreement plans to design and roll out clinical trials for some of BioNTech's priority programs in Poland.
The parties will collaborate to bring innovative treatments to patients quickly, with a focus on cancer immunotherapies.
Ryvu's Chief Operating Officer, Kamil Sitarz, stated that the agreement will leverage Ryvu's operational excellence and expertise in oncology clinical operations to bring more BioNTech clinical programs to Poland.

Statistics:

The agreement aims to accelerate site activation and patient enrollment for multiple of BioNTech's priority oncology clinical programs in Poland.
The clinical programs planned to be included in the agreement span multiple solid tumor types, including lung, breast, and colorectal cancers.
Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology.
BioNTech is a biotechnology company that develops and produces immunotherapies, including cancer immunotherapies.

Sources:

Ryvu Therapeutics (Press Release) - "Ryvu to Support BioNTech in the Acceleration of Site Activation and Enrollment of Patients for Multiple of BioNTech's Priority Oncology Clinical Programs in Poland"